Publikationer pr. år
Publikationer pr. år
Personlig profil
Expertise
Haemato-oncologist. Responsible for treatment of malignant lymphoma and for experimental/phase I treatment of haematological malignancies at Rigshospitalet. Head of service for Hodgkin lymphoma, Mantle cell lymphoma and Castleman’s disease.
Primære forskningsområder
Hodgkin lymphoma; Mantle cell lymphoma; PET/CT in lymphoma; PET-response adapted lymphoma treatment; Phase 1 haematology studies;
Aktuel forskning
Chairman of the EORTC lymphoma group since 2013. Co-author of the international response criteria and guidelines for the use of imaging in lymphoma. Co-author of the European society of Medical Oncology (ESMO) guidelines for Hodgkin lymphoma and ’ultra high-risk’ lymphomas.
Faculty member for the EHA Clinical Research Training in Haematology programme
Member of the scientific committee for the European Haematology Association
National principal investigator or sub-investigator for >25 solid tumour and haematology phase I trials
National principal investigator for three mantle cell lymphoma trials (one ongoing and two planned) and three Hodgkin lymphoma trials.
Site principal investigator or sub-investigator for >20 lymphoma and myeloma phase II and phase III trials
Faculty member for the EHA Clinical Research Training in Haematology programme
Member of the scientific committee for the European Haematology Association
National principal investigator or sub-investigator for >25 solid tumour and haematology phase I trials
National principal investigator for three mantle cell lymphoma trials (one ongoing and two planned) and three Hodgkin lymphoma trials.
Site principal investigator or sub-investigator for >20 lymphoma and myeloma phase II and phase III trials
Mulige interessekonflikter
None
Fingeraftryk
Dyk ned i forskningsemnerne, hvor Martin Hutchings er aktive. Disse emneetiketter kommer fra dennes persons arbejder. Sammen danner de et unikt fingerprint.
- 1 Lignende profiler
Netværk
Seneste eksterne samarbejde på lande-/områdeniveau. Dyk ned i detaljerne ved at klikke på prikkerne eller
-
Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives
Prince, H. M., Hutchings, M., Domingo-Domenech, E., Eichenauer, D. A. & Advani, R., jan. 2023, I: Annals of Hematology. 102, 1, s. 13-29 17 s.Publikation: Bidrag til tidsskrift › Review › peer review
-
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
Fornecker, L-M., Lazarovici, J., Aurer, I., Casasnovas, R-O., Gac, A-C., Bonnet, C., Bouabdallah, K., Feugier, P., Specht, L., Molina, L., Touati, M., Borel, C., Stamatoullas, A., Nicolas-Virelizier, E., Pascal, L., Lugtenburg, P., Di Renzo, N., Vander Borght, T., Traverse-Glehen, A., Dartigues, P., & 6 flere, 10 jan. 2023, I: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41, 2, s. 327-335 9 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
-
Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials - a study based on the EORTC-Dutch late effects cohort linked data
Juul, S. J., Kicinski, M., Schaapveld, M., Rossetti, S., Aleman, B. M. P., Liu, L., van Leeuwen, F. E., Meijnders, P., Krol, A. D. G., Janus, C. P. M., Hutchings, M. & Maraldo, M. V., mar. 2023, I: European Journal of Haematology. 110, 3, s. 243-252 10 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
-
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia
Kreitman, R. J., Moreau, P., Ravandi, F., Hutchings, M., Gazzah, A., Michallet, A-S., Wainberg, Z. A., Stein, A., Dietrich, S., de Jonge, M. J. A., Willenbacher, W., De Grève, J., Arons, E., Ilankumaran, P., Burgess, P., Gasal, E. & Subbiah, V., 2 mar. 2023, I: Blood. 141, 9, s. 996-1006 11 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
-
ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study
Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C. Y., Clausen, M. R., Cunningham, D., Do, Y. R., Feldman, T., Gasiorowski, R., Jurczak, W., Kim, T. M., Lewis, D. J., van der Poel, M., Poon, M. L., Doerr, T., Kilavuz, N., Chen, M., Sacchi, M., Elliott, B., Hutchings, M., & 1 flere, okt. 2022, I: Clinical Lymphoma, Myeloma & Leukemia. 22 Suppl 2, s. S379Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review